Multiple IBD patients have CORVID19, 1 doing well despite Humira + 6MP

"Update 15 March #COVID19 and #IBD. Due to the active communication of colleagues around the globe, we are now aware of several worldwide cases of #COVID19 in patients who have IBD, including one child. "

"Reports that the #IBD adults are in Italy, Austria and US (NJ), the child is in Madrid, Spain.
The child has #Crohns receives Humira + 6MP. She presented with fever and cough, was not hospitalized, and is doing well.
I do not have more details on the adults yet. "

"It was expected that we would see #COVID19 affect our patients with #IBD, as it is affecting the general population too, and it is great that we have systems in place to capture and to learn from these cases in real time. The international collaboration is extraordinary."

"We still recommend that #IBD patients stay on their medical therapies and that staying in remission is best for them. There are active trials underway using some of the anti-cytokine therapies to treat #COVID19 (like anti-TNF and anti-IL6). Recs here: http://ioibd.org"

"Isolation, hand hygiene and vigilance are advised. This week (20 March) there will be an #IOIBD meeting (virtual of course) to review latest info and make additional recommendations. We will all update you then! Stay tuned, stay well. Best wishes. "

Source David T. Rubin, MD:
https://twitter.com/ibdmd/status/1239377121446899713

Source MD in Spanish:
https://twitter.com/flaviostein/status/1239226374126276611

Thanks for always keeping us informed

Thanks, that's a useful website

John, I didn't see on the link where it said that they were using anti tnfs in trials for treatment of covid. Can you point me to where it's at? I want to share it with a friend who is worried about her daughter on Humira

Thanks

I was googling this yesterday. Couldn't find much direct evidence of tnf inhibitors being trialled but I did see a study using IL-6 inhibitors. Also some studies of NAK inhibitors but unfortunately xeljanz did not inhibit the right thing...

Thanks, John!

Ok. Anti cytokene is not (necessarily) the same as anti-tnf

Here is another article published today in the lancet re IL-6 inhibitors and JAK inhibitors

The interesting point is that they mention "a subgroup" of patients might have cytokene storm syndrome, i.e. not everyone with severe illness.

https://www.thelancet.com/journals/lancet/article/piis0140-6736(20)30628-0/fulltext?rss=yes

Here in New York there setting up drive thru test areas.Great idea.N.Y has largest amount of cases in U.S.A

Thanks for those updates! Especially comforting to me that 2 of the patients were on entyvio and not hospitalized!

It's definitely encouraging this far, to know people are doing fine on our meds and with our ages with Corvid19. Our worst, initial fears are not playing out, thankfully. I'm cautiously optimistic!

Here's a firsthand account from a Boston USA patient with UC who got corvid19. He's on Stelara and doing fine, and not hospitalized. He was tested for Corvid19 and confirmed.

https://www.reddit.com/r/crohnsdisease/comments/fknv7s/i_had_a_mild_case_and_am_almost_recovered_from/

Thanks, John! This is great to see.

Daily update from covidibd.org. Still good news.

Updates and Data

3/19/2020 Update

Fourteen cases of COVID-19 have been reported to the registry so far:

United States: A 35 yo female with Crohn’s disease on budesonide. This patient was hospitalized but did not require intensive care or ventilator support.
Spain: A 24 yo female with ulcerative colitis on vedolizumab. This patient did not require hospitalization.
Switzerland: A 23 yo male with Crohn’s disease on Infliximab. The patient did not require hospitalization.
United Kingdom: A 64 yo male with ulcerative colitis on vedolizumab and mesalamine. The patient did not require hospitalization.
United States: A 53 yo female with Crohn’s disease on adalimumab and sirolimus. The patient was hospitalized but did not require intensive care or ventilator support.
United States: A female with ulcerative colitis on prednisone/prednisolone and tofacitinib. The patient did not require hospitalization.
Ireland: A 41 yo male with ulcerative colitis on mesalamine. The patient did not require hospitalization.
Spain: a 50 yo male with ulcerative colitis on tofacitinib. The patient did not require hospitalization.
United States: A male with Crohn’s disease on infliximab. The patient did not require hospitalization.
United States: A 30 yo male with ulcerative colitis on tofacitinib. The patient did not require hospitalization.
United States: A 41 yo male with ulcerative colitis on tofacitinib. The patient did not require hospitalization.
Spain: A 35 yo male with Crohn’s disease on infliximab. The patient did not require hospitalization.
Netherlands: A 52 yo female with ulcerative colitis on infliximab, mesalamine, and 6-mercaptopurine.The patient did not require hospitalization.
Italy: A 63 yo male with Crohn’s disease s/p ileocecal resection not on medication. The patient did not require hospitalization.

No mortalities have been reported to the registry to date.

The average number of days symptoms from COVID-19 among the above cases is 5 days.